Abryl Laboratories was incorporated in 2016 with a single mission—to provide the global market with high quality sterile liquid and lyophilised products. Over the course of time, Abryl has expanded its operations to pre-filled syringes as well.
The project was conceptualised in 2016, followed by the construction commencement in 2017. By May 2019, within just two years, the facility was completely ready for beginning its operations.
The company premises is spread over a sprawling area of 22342 Square Meter and comprises of a manufacturing block and a separate R&D building.
The facility is equipped with modern automated technology to facilitate hassle free production and least human intervention. The facility was designed keeping in mind the latest regulations and guidance from FDA, with adequate sized areas to facilitate operations.
We aim to:
Develop, file and market new products under its own brand name
Provide contract manufacturing facility to top brands, including formulation development, method development studies & stability analysis
Cater to the growing demand for safe medicines and bridge the gap between demand and supply
The facility has a capability to manufacture all generic sterile liquid and lyophilised drugs, as well as pre-filled syringes and can ensure an annual production capacity of :
60 million liquid vials
12 million lyophilised vials
60 million ampoules
10 million PFS.
The following technical arrangements are provided at Abryl
High speed automatic Ampoule Line (Make Truking)
High speed automatic Vial Line 1(Make Truking)
High Speed automatic Vial Line 2(Make Truking)
Freeze Dryer, 2 units of 20 square metre with automatic loading/unloading system(Make Truking)